Rare DNA Mismatch Repair-Related Protein Loss in Patients with Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma and Their Response to Immunotherapy

PURPOSE: The patients with advanced mismatch repair deficiency (dMMR) cancers can benefit from programmed cell death 1 (PD-1) pathway blockade, regardless of the tumor type. Little is known about the prevalence of dMMR in intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular-cholangiocar...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jing, Zhang, Xi, Huang, Qiyue, Tan, Sirui, Xiong, Xianze, Gou, Hongfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183674/
https://www.ncbi.nlm.nih.gov/pubmed/34113169
http://dx.doi.org/10.2147/CMAR.S304281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183674/
https://www.ncbi.nlm.nih.gov/pubmed/34113169
http://dx.doi.org/10.2147/CMAR.S304281

Ejemplares similares